

Ref: FOI/GS/ID 5720

**Please reply to:**  
FOI Administrator  
Trust Management  
Maidstone Hospital  
Hermitage Lane  
Maidstone, Kent  
ME16 9QQ  
Email: mtw-tr.foiadmin@nhs.net

21 September 2020

### **Freedom of Information Act 2000**

I am writing in response to your request for information made under the Freedom of Information Act 2000 in relation to cancer treatments.

*You asked:*

*1. Does your trust treat adult multiple myeloma [MM] ? - if you refer your multiple myeloma patients to another centre, please state which.*

*2. If yes, then how many multiple myeloma patients, have been treated in the past 6 months with the following;*

- Bortezomib [Velcade]*
- Carfilzomib [Kyprolis]*
- Ixazomib [Ninlaro]*
- Lenalidomide [Revlimid]*
- Daratumumab [Darzalex]*
- Melphalan, prednisolone and thalidomide (known as MPT)*
- Cyclophosphamide, thalidomide and dexamethasone (known as CTD)*
- Pomalidomide [Imnovid]*

*3. Over the past 6 months [latest possible], how many chronic lymphocytic leukaemia (CLL) patients have you treated?*

*If possible, how many CLL patients treated were new to therapy in the past 3 months?*

*4. How many chronic lymphocytic leukaemia patients, have been treated in the past 6 months with the following;*

- *Fludarabine (Fludara), cyclophosphamide (Cytosan), and rituximab (known as FCR)*
- *Bendamustine and rituximab (known as BR)*
- *Ibrutinib [Imbruvica]*
- *Chlorambucil*
- *Venetoclax*
- *Obinutuzumab*
- *Idelalisib*
- *Fludarabine and rituximab (known as FR)*
- *High-dose prednisone and rituximab*
- *Pentostatin (Nipent), cyclophosphamide, and rituximab (known as PCR)*
- *Alemtuzumab (Campath) with rituximab*

Trust response:

1. Yes
2. 26
  - Bortezomib [Velcade] 14
  - Lenalidomide [Revlimid] 3
3. 9 of which 6 were new to therapy in the last 3 months.
4. 8
  - Ibrutinib [Imbruvica] 1
  - Chlorambucil 2
  - Obinutuzumab 4